[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Other Articles
December 2003

Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial—Correction

Arch Neurol. 2003;60(12):1728. doi:10.1001/archneur.60.12.1679

Mini-Mental State Examination Scores Erroneously Added. In the Original Contribution by Farlow et al titled "Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial," published in the June issue of the ARCHIVES (2003;60:843-848), 4 Mini-Mental State Examination scores were erroneously added to the text. On page 843, in the "Abstract,""Results" subheading, right-hand column, lines 5 through 9, the sentence should have read: "In these RDO analyses, a statistically significantly greater worsening on the ADAS-Cog mean change score was observed in the placebo group (n = 17) compared with the rivastigmine 6- to 12-mg/d group (n = 33) at week 26."Farther down on the same page, same subsection, lines 13 through 18 should have read: "The RDO analysis also showed a statistically significantly greater decline in cognitive function as measured by the ADAS-Cog mean change score in the placebo group (n = 38) compared with the rivastigmine 6- to 12-mg/d group (n = 88) at week 26." On page 845, "Results" section, "ADAS-Cog Mean Change From Baseline Score" subsection, the first sentence should have read: "The results from the US Pivotal (dose-range) Trial showed a statistically significantly greater worsening on the ADAS-Cog mean change score in the placebo group (n = 17) compared with the rivastigmine 6- to 12-mg/d group (n = 33) at week 26 (Table 2)." Farther down on the page, same subsection lines 9 through 14 should have read: "In the pooled data studies, the RDO analysis also showed a statistically significantly greater decline in cognitive function as measured by the ADAS-Cog mean change score in the placebo group (n = 38) compared with the rivastigmine 6- to 12-mg/d group (n = 88) at 26 weeks."

First Page Preview View Large
First page PDF preview
First page PDF preview
×